The Adjunctive Effect of a Titanium Brush in the Non-Surgical Treatment of Peri-Implantitis
NCT ID: NCT06843928
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
36 participants
INTERVENTIONAL
2024-06-12
2026-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Implant Healing Abutment and Chlorhexidine
NCT03142828
Efficacy of Photodynamic Therapy in the Non-Surgical Treatment of Peri-Implantitis
NCT07191522
Non-surgical Treatment of Peri-implantitis Using Chitosan Brush and Tetracycline Slurry
NCT06695559
A NEW MECHANICAL DECONTAMINATION METHOD IN PERI-IMPLANTITIS, TI-BRUSH, A RANDOMIZED CONTROLLED CLINICAL TRIAL
NCT03512730
The Effect of Peri-implant Surgery and Chair-side Supportive Post Surgical Peri-implant Therapy
NCT03421717
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Participants will receive submucosal debridement alone
Submucosal debridement
Participants will undergo non-surgical submucosal debridement alone (SD)
Submucosal debridement + titanium brushes
Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
Test Group
Participants will receive submucosal debridement and titanium brushes
Submucosal debridement
Participants will undergo non-surgical submucosal debridement alone (SD)
Submucosal debridement + titanium brushes
Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Submucosal debridement
Participants will undergo non-surgical submucosal debridement alone (SD)
Submucosal debridement + titanium brushes
Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to understand all the study procedures and to comply with them along the entire study period. Ability and willingness to give written informed consent.
* An adequate level of oral hygiene (plaque index ≤ 25%) (O'Leary et al., 1972).
* Treated periodontal disease.
* Presence of at least one titanium implant with peri-implantitis \[i.e., presence of bleeding and/or suppuration on gentle probing with probing depth of ≥6 mm, and progressive bone loss. In the absence of initial radiographs, a bone level ≥2 mm apical to the most coronal part of the intrabony portion of the implant will be used as threshold of disease (Romandini et al., 2021)\].
* Horizontal and vertical peri-implant bone defects.
* Implant function time ≥ 1 year.
* Presence of ≥2mm of keratinized peri-implant mucosa.
* Screw-retained single and multiple restorations.
Exclusion Criteria
* Smokers \> 10 cigarettes per day.
* Local or systemic diseases that would interfere with routine periodontal therapy (i.e., uncontrolled diabetes mellitus, cancer, HIV, chronic high-dose steroid therapy, metabolic bone disease, radiation, immunosuppressive disease, hepatic dysfunction, immunosuppressive disease, autoimmune disease).
* Pregnant or lactating women.
* Previous surgical and non-surgical treatment of affected implants at least 12 months prior to the beginning of the study.
* Radiographic peri-implant bone loss \> two-thirds.
* Mobility of the implant.
* Known allergy or intolerance to macrolides.
* Use of systemic antibiotics during the last 3 months.
* Need of endocarditis prophylaxis.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitat Internacional de Catalunya
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Javi Vilarrasa
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitat Internacional de Catalunya
Barcelona, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PER-ECL-2024-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.